Ignite Creation Date:
2025-12-25 @ 3:05 AM
Ignite Modification Date:
2026-01-01 @ 3:51 AM
Study NCT ID:
NCT06874933
Status:
RECRUITING
Last Update Posted:
2025-08-12
First Post:
2025-03-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)
Sponsor:
First Affiliated Hospital of Zhejiang University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-05-04
Start Date Type:
ACTUAL
Primary Completion Date:
2027-04-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-04-01
Completion Date Type:
ESTIMATED
First Submit Date:
2025-03-10
First Submit QC Date:
None
Study First Post Date:
2025-03-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-11
Last Update Post Date:
2025-08-12
Last Update Post Date Type:
ACTUAL